Advertisement Pharmaceutical Business review - Page 715 of 5273 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 14, 2026

Zydus to acquire Assertio in $166m deal

Zydus Lifesciences (Zydus) is set to acquire all outstanding Assertio common shares in a deal valued at around $166.4m, through its subsidiary Zydus Worldwide DMCC.

Upon completion of the tender, Zydus will acquire any remaining shares through a second-step merger at the same price. Credit: Piotr Swat / Shutterstock.com.